Momegalen (Mometasone Furoate Ph. Eur.)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal passages. This interaction modifies gene expression, suppresses the release of inflammatory cytokines, reduces leukocyte infiltration, and stabilises cell membranes, leading to decreased nasal inflammation.

The exact dosing regimen is determined by the prescribing healthcare professional. Typically, the product is administered as one or two sprays per nostril once daily, but the prescriber will set the appropriate dose based on the patient’s condition and response.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against possible risks before prescribing it to pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Momegalen (mometasone furoate) is a high‑potency nasal corticosteroid with a favorable safety profile when used as directed. Compared with alternatives such as fluticasone propionate, it offers similar efficacy in reducing nasal inflammation but may have a slightly longer residence time in the nasal mucosa, allowing once‑daily dosing for many patients.

Store the nasal spray at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight and excessive heat. Do not freeze the product, and ensure the cap is tightly closed when not in use.

Momegalen is administered intranasally. The user gently shakes the bottle, removes the protective cap, and sprays the prescribed number of sprays into each nostril while keeping the head upright. The spray should be directed away from the nasal septum to minimize irritation.

Serious risks, although rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, vision changes (e.g., cataracts or glaucoma), and systemic adrenal suppression with prolonged high‑dose use. Patients should report any unusual symptoms promptly to their healthcare provider.

Momegalen should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated fungal, viral or bacterial infections of the nasal passages until the infection is resolved.